Floatz Rating
B57/100
Confidence
Indicative
Sponsor
National University of Singapore
Modality
protein_peptide
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cerebral Atherosclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dulaglutide (this asset) | National University of Singapore | P2/3 | B · 57 |
| Ferumoxytol | Northwestern University | P4 | BB |
| Atorvastatin | General Hospital of Shenyang Military Region | P4 | BB |
| Probucol | General Hospital of Shenyang Military Region | P4 | BB |
| Rucacuzumab | Peking Union Medical College Hospital | P4 | BB |
| Immunoglobulin G1 (256-Tyrosine,258-Threonine,260-Glutamic Acid), Anti-(Neural Apoptosis-Regulated Proteinase 1) (Human-Mus Musculus Monoclonal Hrp00130 .Gamma.1-Chain), Disulfide With (3-Valine,5-Serine,49-Serine,66-Aspartic Acid) Human-Mus Musculus Monoclonal Hrp00130 .Kappa.-Chain, Dimer | Peking Union Medical College Hospital | P4 | BB |
| Rosuvastatin | Samsung Medical Center | P4 | BB |
| Rivaroxaban | Population Health Research Institute | P3 | BB |
| Aspirin | Population Health Research Institute | P3 | BB |
+4 more in the Cerebral Atherosclerosis cohort
Other indications for Dulaglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glucose Intolerance | — | P4 | BBB · 75 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BB · 65 |
| Hyperglycemia | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FerumoxytolNorthwestern UniversityBB
- AtorvastatinGeneral Hospital of Shenyang Military RegionBB
- ProbucolGeneral Hospital of Shenyang Military RegionBB
- RucacuzumabPeking Union Medical College HospitalBB
- Immunoglobulin G1 (256-Tyrosine,258-Threonine,260-Glutamic Acid), Anti-(Neural Apoptosis-Regulated Proteinase 1) (Human-Mus Musculus Monoclonal Hrp00130 .Gamma.1-Chain), Disulfide With (3-Valine,5-Serine,49-Serine,66-Aspartic Acid) Human-Mus Musculus Monoclonal Hrp00130 .Kappa.-Chain, DimerPeking Union Medical College HospitalBB
Citation
Floatz Terminal. Dulaglutide in Cerebral Atherosclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dulaglutide-cerebral-atherosclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →